Will the FDA change how it vets drugs following the Alzheimer's debacle?


13 May 2022 - The accelerated approval of aducanumab has triggered US law makers to push for more oversight from the agency.

Nearly a year after the U.S. FDA gave the green light to a controversial drug to treat Alzheimer’s disease, law makers are attempting to amend the process that led to its approval.

Read Nature article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation